RPL17 and gastric cancer: In recent years, the PD - 1/PD-L1 pathway remains a central focus of immunotherapy research, with inhibitors targeting this axis approved for the treatment of several solid tumors, including hepatocellular carcinoma, colorectal cancer, and GC.